Journal
IMMUNITY
Volume 53, Issue 4, Pages 824-+Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2020.09.006
Keywords
-
Categories
Funding
- Fondation ARC [PGA1-20160203788, 20180206911, 20190208630]
- Institut National du Cancer (INCA) [PLBIO R16100BB, 2017-155]
- Cancer Research Institute/Bristol-Myers Squibb CLIP Grant
- Fondation Toulouse cancer sante
- Ligue contre le cancer
- European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
- Fondation Recherche Medicale [FRM DEQ20170336727]
- Dr. Mildred Scheel Stiftung fuer Krebsforschung'' of the Deutsche Krebshilfe
- EMBO [ALT945-2015]
- National Health and Medical Research Council of Australia grant (NHMRC) [1124690]
- NHMRC [1078671, 1173958, 1132519]
- Cancer Council of Queensland Project Grant [1157048]
- Fonds National de la Recherche Scientifique'' (FRS-FNRS, Belgium)
- European Regional Development Fund (ERDF) of the Walloon Region (Wallonia-Biomed portfolio) [411132-957270]
- IUCT-O translational research program
Ask authors/readers for more resources
CD8(+) T cells within the tumor microenvironment (TME) are exposed to various signals that ultimately determine functional outcomes. Here, we examined the role of the co-activating receptor CD226 (DNAM-1) in CD8(+) T cell function. The absence of CD226 expression identified a subset of dysfunctional CD8(+) T cells present in peripheral blood of healthy individuals. These cells exhibited reduced LFA-1 activation, altered TCR signaling, and a distinct transcriptomic program upon stimulation. CD226(neg) CD8(+) T cells accumulated in human and mouse tumors of diverse origin through an antigen-specific mechanism involving the transcriptional regulator Eomesodermin (Eomes). Despite similar expression of co-inhibitory receptors, CD8(+) tumor-infiltrating lymphocyte failed to respond to anti-PD-1 in the absence of CD226. Immune checkpoint blockade efficacy was hampered in Cd226(-/-) mice. Anti-CD137 (4-1 BB) agonists also stimulated Eomes-dependent CD226 loss that limited the anti-tumor efficacy of this treatment. Thus, CD226 loss restrains CD8(+) T cell function and limits the efficacy of cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available